CRAVES FRED B

SEC source: 0000899243-21-047115 · doc4.xml · nonDerivative · entry 1

CRAVES FRED B · CIK 0001014095 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 1,510,521

F7 · kind: Represents transfers, without the payment of any consideration, to their partners and employees.

F1 · ownership.nature: Bay City Capital LLC, a Delaware limited liability company ("BCC"), Bay City Capital Management IV LLC, a Delaware limited liability company ("Management IV"), Bay City Capital Fund IV, L.P., a Delaware limited partnership ("Fund IV"), and Bay City Capital Fund IV Co-Investment Fund, L.P., a Delaware limited partnership ("Co-Investment IV") are deemed to be a "group" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management IV is the general partner of Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV. BCC, the manager of Management IV, is also an advisor to Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV.

F2 · ownership.nature: These securities are held by Fund IV. Dr. Craves disclaims beneficial ownership of these securities held by Fund IV, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in BCC.

SEC source: 0000899243-21-024668 · doc4.xml · derivative · entry 1

CRAVES FRED B · CIK 0001014095 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,489

Underlying: Common Stock · 12,489 shares

Expires 2024-06-17

F1 · derivative.exercise_date: The option vests as to 100% of underlying shares on the first anniversary of the grant date, provided that the Reporting Person continues to serve as a director of the Issuer until such anniversary date.

SEC source: 0000899243-21-005912 · doc5.xml · nonDerivative · entry 2

CRAVES FRED B · CIK 0001014095 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 317,579

F3 · kind: Represents a bona fide gift of 15,000 shares of common stock from Dr. Craves to the Fred Craves Family Foundation.

F4 · balance_after: Reflects a transfer of 43,537 shares of common stock from BCC to Dr. Craves and a transfer of 80,974 shares of common stock from Dr. Craves to a former spouse pursuant to a court approved divorce settlement agreement.

F3 · ownership.direct: Represents a bona fide gift of 15,000 shares of common stock from Dr. Craves to the Fred Craves Family Foundation.

F4 · ownership.direct: Reflects a transfer of 43,537 shares of common stock from BCC to Dr. Craves and a transfer of 80,974 shares of common stock from Dr. Craves to a former spouse pursuant to a court approved divorce settlement agreement.

SEC source: 0000899243-20-024410 · doc4.xml · nonDerivative · entry 3

CRAVES FRED B · CIK 0001014095 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 43,537

F6 · kind: Represents transfers, without the payment of any consideration, to their partners and employees.

F6 · shares: Represents transfers, without the payment of any consideration, to their partners and employees.

F6 · price: Represents transfers, without the payment of any consideration, to their partners and employees.

F6 · acquired: Represents transfers, without the payment of any consideration, to their partners and employees.

F1 · ownership.nature: Bay City Capital LLC, a Delaware limited liability company ("BCC"), Bay City Capital Management IV LLC, a Delaware limited liability company ("Management IV"), Bay City Capital Fund IV, L.P., a Delaware limited partnership ("Fund IV"), and Bay City Capital Fund IV Co-Investment Fund, L.P., a Delaware limited partnership ("Co-Investment IV") are deemed to be a "group" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management IV is the general partner of Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV. BCC, the manager of Management IV, is also an advisor to Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV.

F4 · ownership.nature: These securities are held by BCC. Dr. Craves disclaims beneficial ownership of these securities held by BCC, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in BCC.

SEC source: 0000899243-20-024410 · doc4.xml · nonDerivative · entry 2

CRAVES FRED B · CIK 0001014095 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 49,730

F6 · kind: Represents transfers, without the payment of any consideration, to their partners and employees.

F6 · shares: Represents transfers, without the payment of any consideration, to their partners and employees.

F6 · price: Represents transfers, without the payment of any consideration, to their partners and employees.

F6 · acquired: Represents transfers, without the payment of any consideration, to their partners and employees.

F1 · ownership.nature: Bay City Capital LLC, a Delaware limited liability company ("BCC"), Bay City Capital Management IV LLC, a Delaware limited liability company ("Management IV"), Bay City Capital Fund IV, L.P., a Delaware limited partnership ("Fund IV"), and Bay City Capital Fund IV Co-Investment Fund, L.P., a Delaware limited partnership ("Co-Investment IV") are deemed to be a "group" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management IV is the general partner of Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV. BCC, the manager of Management IV, is also an advisor to Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV.

F3 · ownership.nature: These securities are held by Co-Investment IV. Dr. Craves disclaims beneficial ownership of these securities held by Co-Investment IV, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in BCC.

SEC source: 0000899243-20-024410 · doc4.xml · nonDerivative · entry 1

CRAVES FRED B · CIK 0001014095 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,260,791

F6 · kind: Represents transfers, without the payment of any consideration, to their partners and employees.

F6 · shares: Represents transfers, without the payment of any consideration, to their partners and employees.

F6 · price: Represents transfers, without the payment of any consideration, to their partners and employees.

F6 · acquired: Represents transfers, without the payment of any consideration, to their partners and employees.

F1 · ownership.nature: Bay City Capital LLC, a Delaware limited liability company ("BCC"), Bay City Capital Management IV LLC, a Delaware limited liability company ("Management IV"), Bay City Capital Fund IV, L.P., a Delaware limited partnership ("Fund IV"), and Bay City Capital Fund IV Co-Investment Fund, L.P., a Delaware limited partnership ("Co-Investment IV") are deemed to be a "group" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management IV is the general partner of Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV. BCC, the manager of Management IV, is also an advisor to Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV.

F2 · ownership.nature: These securities are held by Fund IV. Dr. Craves disclaims beneficial ownership of these securities held by Fund IV, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in BCC.

SEC source: 0000899243-20-022971 · doc4.xml · nonDerivative · entry 3

CRAVES FRED B · CIK 0001014095 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 42,875

F1 · ownership.nature: Bay City Capital LLC, a Delaware limited liability company ("BCC"), Bay City Capital Management IV LLC, a Delaware limited liability company ("Management IV"), Bay City Capital Fund IV, L.P., a Delaware limited partnership ("Fund IV"), and Bay City Capital Fund IV Co-Investment Fund, L.P., a Delaware limited partnership ("Co-Investment IV") are deemed to be a "group" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management IV is the general partner of Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV. BCC, the manager of Management IV, is also an advisor to Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV.

F2 · ownership.nature: These securities are held by BCC. Dr. Craves disclaims beneficial ownership of these securities held by BCC, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in BCC.

SEC source: 0000899243-20-022971 · doc4.xml · nonDerivative · entry 2

CRAVES FRED B · CIK 0001014095 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 50,178

F1 · ownership.nature: Bay City Capital LLC, a Delaware limited liability company ("BCC"), Bay City Capital Management IV LLC, a Delaware limited liability company ("Management IV"), Bay City Capital Fund IV, L.P., a Delaware limited partnership ("Fund IV"), and Bay City Capital Fund IV Co-Investment Fund, L.P., a Delaware limited partnership ("Co-Investment IV") are deemed to be a "group" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management IV is the general partner of Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV. BCC, the manager of Management IV, is also an advisor to Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV.

F2 · ownership.nature: These securities are held by BCC. Dr. Craves disclaims beneficial ownership of these securities held by BCC, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in BCC.

SEC source: 0000899243-20-022971 · doc4.xml · nonDerivative · entry 1

CRAVES FRED B · CIK 0001014095 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 60,375

F1 · ownership.nature: Bay City Capital LLC, a Delaware limited liability company ("BCC"), Bay City Capital Management IV LLC, a Delaware limited liability company ("Management IV"), Bay City Capital Fund IV, L.P., a Delaware limited partnership ("Fund IV"), and Bay City Capital Fund IV Co-Investment Fund, L.P., a Delaware limited partnership ("Co-Investment IV") are deemed to be a "group" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management IV is the general partner of Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV. BCC, the manager of Management IV, is also an advisor to Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV.

F2 · ownership.nature: These securities are held by BCC. Dr. Craves disclaims beneficial ownership of these securities held by BCC, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in BCC.

SEC source: 0000899243-20-016983 · doc4.xml · derivative · entry 1

CRAVES FRED B · CIK 0001014095 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,000

Underlying: Common Stock · 6,000 shares

Expires 2025-06-17

F1 · derivative.exercise_date: The option vests as to 100% of underlying shares on the first anniversary of the grant date, provided that the Reporting Person continues to serve as a director of the Issuer until such anniversary date.

SEC source: 0000899243-20-014568 · doc4.xml · nonDerivative · entry 3

CRAVES FRED B · CIK 0001014095 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 72,875

F5 · kind: Represents transfers, without the payment of any consideration, to their partners and employees.

F5 · shares: Represents transfers, without the payment of any consideration, to their partners and employees.

F5 · price: Represents transfers, without the payment of any consideration, to their partners and employees.

F5 · acquired: Represents transfers, without the payment of any consideration, to their partners and employees.

F1 · ownership.nature: Bay City Capital LLC, a Delaware limited liability company ("BCC"), Bay City Capital Management IV LLC, a Delaware limited liability company ("Management IV"), Bay City Capital Fund IV, L.P., a Delaware limited partnership ("Fund IV"), and Bay City Capital Fund IV Co-Investment Fund, L.P., a Delaware limited partnership ("Co-Investment IV") are deemed to be a "group" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management IV is the general partner of Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV. BCC, the manager of Management IV, is also an advisor to Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV.

F4 · ownership.nature: These securities are held by BCC. Dr. Craves disclaims beneficial ownership of these securities held by BCC, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in BCC.

SEC source: 0000899243-20-014568 · doc4.xml · nonDerivative · entry 2

CRAVES FRED B · CIK 0001014095 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 81,380

F5 · kind: Represents transfers, without the payment of any consideration, to their partners and employees.

F5 · shares: Represents transfers, without the payment of any consideration, to their partners and employees.

F5 · price: Represents transfers, without the payment of any consideration, to their partners and employees.

F5 · acquired: Represents transfers, without the payment of any consideration, to their partners and employees.

F1 · ownership.nature: Bay City Capital LLC, a Delaware limited liability company ("BCC"), Bay City Capital Management IV LLC, a Delaware limited liability company ("Management IV"), Bay City Capital Fund IV, L.P., a Delaware limited partnership ("Fund IV"), and Bay City Capital Fund IV Co-Investment Fund, L.P., a Delaware limited partnership ("Co-Investment IV") are deemed to be a "group" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management IV is the general partner of Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV. BCC, the manager of Management IV, is also an advisor to Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV.

F3 · ownership.nature: These securities are held by Co-Investment IV. Dr. Craves disclaims beneficial ownership of these securities held by Co-Investment IV, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in BCC.

SEC source: 0000899243-20-014568 · doc4.xml · nonDerivative · entry 1

CRAVES FRED B · CIK 0001014095 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,729,141

F5 · kind: Represents transfers, without the payment of any consideration, to their partners and employees.

F5 · shares: Represents transfers, without the payment of any consideration, to their partners and employees.

F5 · price: Represents transfers, without the payment of any consideration, to their partners and employees.

F5 · acquired: Represents transfers, without the payment of any consideration, to their partners and employees.

F1 · ownership.nature: Bay City Capital LLC, a Delaware limited liability company ("BCC"), Bay City Capital Management IV LLC, a Delaware limited liability company ("Management IV"), Bay City Capital Fund IV, L.P., a Delaware limited partnership ("Fund IV"), and Bay City Capital Fund IV Co-Investment Fund, L.P., a Delaware limited partnership ("Co-Investment IV") are deemed to be a "group" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management IV is the general partner of Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV. BCC, the manager of Management IV, is also an advisor to Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV.

F2 · ownership.nature: These securities are held by Fund IV. Dr. Craves disclaims beneficial ownership of these securities held by Fund IV, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in BCC.

SEC source: 0001562180-20-001620 · primarydocument.xml · derivative · entry 10

CRAVES FRED B · CIK 0001014095 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,000 shares

Expires not disclosed

F7 · derivative.exercise_price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price.

F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.

F7 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price.

F7 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price.

F7 · derivative.expiration_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price.

SEC source: 0001562180-20-001620 · primarydocument.xml · derivative · entry 9

CRAVES FRED B · CIK 0001014095 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,000 shares

Expires 2029-06-03

F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.

F6 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.

F6 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.

SEC source: 0001562180-20-001620 · primarydocument.xml · derivative · entry 8

CRAVES FRED B · CIK 0001014095 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,000 shares

Expires 2028-06-12

F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.

F6 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.

F6 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.

SEC source: 0001562180-20-001620 · primarydocument.xml · derivative · entry 7

CRAVES FRED B · CIK 0001014095 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,000 shares

Expires 2027-06-12

F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.

F6 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.

F6 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.

SEC source: 0001562180-20-001620 · primarydocument.xml · derivative · entry 6

CRAVES FRED B · CIK 0001014095 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,344 shares

Expires 2026-06-20

F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.

F6 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.

F6 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.

SEC source: 0001562180-20-001620 · primarydocument.xml · derivative · entry 5

CRAVES FRED B · CIK 0001014095 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,334 shares

Expires 2025-06-10

F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.

F6 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.

F6 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.

SEC source: 0001562180-20-001620 · primarydocument.xml · nonDerivative · entry 4

CRAVES FRED B · CIK 0001014095 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote 5

Disclosed balance after: 0

F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.

F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.

F5 · ownership.nature: The securities are held directly by the Fred Craves Family Foundation ("Foundation"). Dr. Craves serves as the chief executive officer of the Foundation. Dr. Craves disclaims beneficial ownership over and does not have a pecuniary interest in shares held by the Foundation. This report shall not be deemed an admission that the Dr. Craves is the beneficial owner of such shares.

SEC source: 0001562180-20-001620 · primarydocument.xml · nonDerivative · entry 3

CRAVES FRED B · CIK 0001014095 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote 4

Disclosed balance after: 0

F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.

F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.

F4 · ownership.nature: The securities are held directly by Bay City Capital Fund V Co-Investment Fund, L.P. ("Co-Investment V"). Dr. Craves disclaims beneficial ownership over the securities owned by Co-Investment V, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in Bay City Capital LLC, which is the manager of Co-Investment V's general partner, Bay City Capital Management V LLC.

SEC source: 0001562180-20-001620 · primarydocument.xml · nonDerivative · entry 2

CRAVES FRED B · CIK 0001014095 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote 3

Disclosed balance after: 0

F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.

F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.

F3 · ownership.nature: The securities are held directly by Bay City Capital Fund V, L.P. ("Fund V"). Dr. Craves disclaims beneficial ownership over the securities owned by Fund V, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in Bay City Capital LLC, which is the manager of Fund V's general partner, Bay City Capital Management V LLC.

SEC source: 0001562180-20-001620 · primarydocument.xml · nonDerivative · entry 1

CRAVES FRED B · CIK 0001014095 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote 2

Disclosed balance after: 0

F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.

F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.

F2 · ownership.nature: The securities are held directly by Bay City Capital LLC ("BCC LLC"). Dr. Craves disclaims beneficial ownership over the securities owned by BCC LLC except to the extent of his pecuniary interest, if any, in the securities by virtue of his role as managing director of BCC LLC. This report shall not be deemed an admission that the Dr. Craves is the beneficial owner of such shares.

SEC source: 0000899243-19-029135 · doc4.xml · nonDerivative · entry 2

CRAVES FRED B · CIK 0001014095 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 88,152

F1 · ownership.nature: Bay City Capital LLC, a Delaware limited liability company ("BCC"), Bay City Capital Management IV LLC, a Delaware limited liability company ("Management IV"), Bay City Capital Fund IV, L.P., a Delaware limited partnership ("Fund IV"), and Bay City Capital Fund IV Co-Investment Fund, L.P., a Delaware limited partnership ("Co-Investment IV") are deemed to be a "group" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management IV is the general partner of Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV. BCC, the manager of Management IV, is also an advisor to Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV.

F3 · ownership.nature: These securities are held by Co-Investment IV. Dr. Craves disclaims beneficial ownership of these securities held by Co-Investment IV, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in BCC.

SEC source: 0000899243-19-029135 · doc4.xml · nonDerivative · entry 1

CRAVES FRED B · CIK 0001014095 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 4,089,702

F1 · ownership.nature: Bay City Capital LLC, a Delaware limited liability company ("BCC"), Bay City Capital Management IV LLC, a Delaware limited liability company ("Management IV"), Bay City Capital Fund IV, L.P., a Delaware limited partnership ("Fund IV"), and Bay City Capital Fund IV Co-Investment Fund, L.P., a Delaware limited partnership ("Co-Investment IV") are deemed to be a "group" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management IV is the general partner of Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV. BCC, the manager of Management IV, is also an advisor to Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV.

F2 · ownership.nature: These securities are held by Fund IV. Dr. Craves disclaims beneficial ownership of these securities held by Fund IV, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in BCC.

SEC source: 0001209191-19-052820 · doc4.xml · derivative · entry 1

CRAVES FRED B · CIK 0001014095 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,590

Underlying: Common Stock · 5,590 shares

Expires 2029-07-22

F1 · derivative.exercise_date: 100% of the shares subject to the option will vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Issuer's first annual meeting of stockholders following the date of grant, subject to the Reporting Person's continuous service through each vesting date.

SEC source: 0000899243-19-018656 · doc4.xml · derivative · entry 1

CRAVES FRED B · CIK 0001014095 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2024-06-27

F1 · derivative.exercise_date: The option vests as to 100% of underlying shares on the first anniversary of the grant date, provided that the Reporting Person continues to serve as a director of the Issuer until such anniversary date.

SEC source: 0001562180-19-003534 · primarydocument.xml · derivative · entry 5

CRAVES FRED B · CIK 0001014095 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote 1

Disclosed balance after: 0

Underlying: Common Stock · 3,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of DERM common stock.

F6 · derivative.exercise_date: The RSU, which was granted on June 12, 2018, fully vested on June 12, 2019.

F5 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of DERM common stock.

F1 · ownership.nature: The securities are held directly by Bay City Capital LLC ("BCC LLC") and represent shares issued upon the vesting of restricted stock units granted to Dr. Craves and transferred to BCC LLC pursuant to an agreement between Dr. Craves and BCC LLC. Dr. Craves disclaims beneficial ownership over the securities owned by BCC LLC except to the extent of his pecuniary interest, if any, in the securities by virtue of his role as managing director of BCC LLC. This report shall not be deemed an admission that the Dr. Craves is the beneficial owner of such shares.

SEC source: 0001562180-19-003534 · primarydocument.xml · nonDerivative · entry 1

CRAVES FRED B · CIK 0001014095 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote 1

Disclosed balance after: 6,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: The securities are held directly by Bay City Capital LLC ("BCC LLC") and represent shares issued upon the vesting of restricted stock units granted to Dr. Craves and transferred to BCC LLC pursuant to an agreement between Dr. Craves and BCC LLC. Dr. Craves disclaims beneficial ownership over the securities owned by BCC LLC except to the extent of his pecuniary interest, if any, in the securities by virtue of his role as managing director of BCC LLC. This report shall not be deemed an admission that the Dr. Craves is the beneficial owner of such shares.

SEC source: 0001562180-19-003408 · primarydocument.xml · derivative · entry 6

CRAVES FRED B · CIK 0001014095 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Bay City Capital LLC

Disclosed balance after: 3,000

Underlying: Common Stock · 3,000 shares

Expires not disclosed

F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of DERM common stock.

F7 · derivative.exercise_date: The RSU will vest 100% of the shares on June 4, 2020, subject to the continuing service of the Reporting Person on such vesting date.

F6 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of DERM common stock.

SEC source: 0001562180-19-003408 · primarydocument.xml · derivative · entry 5

CRAVES FRED B · CIK 0001014095 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Bay City Capital LLC

Disclosed balance after: 6,000

Underlying: Common Stock · 6,000 shares

Expires 2029-06-03

F5 · derivative.exercise_date: The stock option will vest and become exercisable as to 100% of the shares on June 4, 2020, subject to the continuing service of the Reporting Person on such vesting date.

SEC source: 0001179110-18-013009 · edgar.xml · nonDerivative · entry 3

CRAVES FRED B · CIK 0001014095 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 298,067

SEC source: 0001179110-18-013009 · edgar.xml · nonDerivative · entry 2

CRAVES FRED B · CIK 0001014095 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 297,167

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.00 to $124.82, inclusive. Thereporting person undertakes to provide to Madrigal Pharmaceuticals, Inc., any security holder of Madrigal Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

SEC source: 0001179110-18-013009 · edgar.xml · nonDerivative · entry 1

CRAVES FRED B · CIK 0001014095 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 296,167

SEC source: 0001209191-18-057430 · doc4.xml · derivative · entry 7

CRAVES FRED B · CIK 0001014095 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By The Craves Family Foundation

Disclosed balance after: 0

Underlying: Common Stock · 8,603 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock have no expiration date and converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: The Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock have no expiration date and converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering.

F1 · derivative.expiration_date: The Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock have no expiration date and converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering.

F2 · ownership.nature: The Reporting Person is a trustee of The Craves Family Foundation. The Reporting Person may be deemed to have voting and dispositive power over the shares held of record by The Craves Family Foundation. The Reporting Person disclaims beneficial ownership in these shares except as to the Reporting Person's pecuniary interest therein.

SEC source: 0001209191-18-057430 · doc4.xml · derivative · entry 6

CRAVES FRED B · CIK 0001014095 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By The Craves Family Foundation

Disclosed balance after: 0

Underlying: Common Stock · 7,158 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock have no expiration date and converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: The Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock have no expiration date and converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering.

F1 · derivative.expiration_date: The Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock have no expiration date and converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering.

F2 · ownership.nature: The Reporting Person is a trustee of The Craves Family Foundation. The Reporting Person may be deemed to have voting and dispositive power over the shares held of record by The Craves Family Foundation. The Reporting Person disclaims beneficial ownership in these shares except as to the Reporting Person's pecuniary interest therein.

SEC source: 0001209191-18-057430 · doc4.xml · derivative · entry 5

CRAVES FRED B · CIK 0001014095 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By The Craves Family Foundation

Disclosed balance after: 0

Underlying: Common Stock · 51,010 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock have no expiration date and converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: The Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock have no expiration date and converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering.

F1 · derivative.expiration_date: The Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock have no expiration date and converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering.

F2 · ownership.nature: The Reporting Person is a trustee of The Craves Family Foundation. The Reporting Person may be deemed to have voting and dispositive power over the shares held of record by The Craves Family Foundation. The Reporting Person disclaims beneficial ownership in these shares except as to the Reporting Person's pecuniary interest therein.

SEC source: 0001209191-18-057430 · doc4.xml · nonDerivative · entry 3

CRAVES FRED B · CIK 0001014095 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Craves Family Foundation

Disclosed balance after: 66,771

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock have no expiration date and converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering.

F2 · ownership.nature: The Reporting Person is a trustee of The Craves Family Foundation. The Reporting Person may be deemed to have voting and dispositive power over the shares held of record by The Craves Family Foundation. The Reporting Person disclaims beneficial ownership in these shares except as to the Reporting Person's pecuniary interest therein.

SEC source: 0001209191-18-057430 · doc4.xml · nonDerivative · entry 2

CRAVES FRED B · CIK 0001014095 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Craves Family Foundation

Disclosed balance after: 58,168

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock have no expiration date and converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering.

F2 · ownership.nature: The Reporting Person is a trustee of The Craves Family Foundation. The Reporting Person may be deemed to have voting and dispositive power over the shares held of record by The Craves Family Foundation. The Reporting Person disclaims beneficial ownership in these shares except as to the Reporting Person's pecuniary interest therein.

SEC source: 0001209191-18-057430 · doc4.xml · nonDerivative · entry 1

CRAVES FRED B · CIK 0001014095 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Craves Family Foundation

Disclosed balance after: 51,010

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock have no expiration date and converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering.

F2 · ownership.nature: The Reporting Person is a trustee of The Craves Family Foundation. The Reporting Person may be deemed to have voting and dispositive power over the shares held of record by The Craves Family Foundation. The Reporting Person disclaims beneficial ownership in these shares except as to the Reporting Person's pecuniary interest therein.

SEC source: 0001179110-18-008925 · edgar.xml · derivative · entry 1

CRAVES FRED B · CIK 0001014095 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2028-06-19

F1 · derivative.exercise_date: The option vests as to 100% of underlying shares on the first anniversary of the grant date, provided that the Reporting Person continues to serve as a director of the Issuer until such anniversary date.

SEC source: 0001562180-18-003006 · primarydocument.xml · derivative · entry 7

CRAVES FRED B · CIK 0001014095 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of DERM common stock.

F8 · derivative.exercise_date: The RSU, which was granted on June 13, 2017, fully vested on June 13, 2018.

F6 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of DERM common stock.

SEC source: 0001562180-18-003006 · primarydocument.xml · nonDerivative · entry 1

CRAVES FRED B · CIK 0001014095 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · date: Represents shares acquired upon vesting of RSU granted on June 13, 2017.

SEC source: 0001562180-18-003006 · primarydocument.xml · derivative · entry 6

CRAVES FRED B · CIK 0001014095 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,000

Underlying: Common Stock · 3,000 shares

Expires not disclosed

F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of DERM common stock.

F7 · derivative.exercise_date: The RSU will vest 100% of the shares on June 12, 2019, subject to the continuing service of the Reporting Person on such vesting date.

F6 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of DERM common stock.

SEC source: 0001562180-18-003006 · primarydocument.xml · derivative · entry 5

CRAVES FRED B · CIK 0001014095 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,000

Underlying: Common Stock · 6,000 shares

Expires 2028-06-12

F5 · derivative.exercise_date: The stock option will vest and become exercisable as to 100% of the shares on June 12, 2019, subject to the continuing service of the Reporting Person on such vesting date.

SEC source: 0001179110-18-008430 · edgar.xml · nonDerivative · entry 2

CRAVES FRED B · CIK 0001014095 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 113,472

F1 · ownership.nature: Bay City Capital LLC, a Delaware limited liability company ("BCC"), Bay City Capital Management IV LLC, a Delaware limited liability company ("Management IV"), BayCity Capital Fund IV, L.P., a Delaware limited partnership ("Fund IV"), and Bay City Capital Fund IV Co-Investment Fund, L.P., a Delaware limited partnership ("Co-InvestmentIV") are deemed to be a "group" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management IV is the general partner of Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV. BCC, the manager of Management IV, is also anadvisor to Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV.

F3 · ownership.nature: These securities are held by Co-Investment IV. Dr. Craves disclaims beneficial ownership of these securities held by Co-Investment IV, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in BCC.

SEC source: 0001179110-18-008430 · edgar.xml · nonDerivative · entry 1

CRAVES FRED B · CIK 0001014095 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 5,264,382

F1 · ownership.nature: Bay City Capital LLC, a Delaware limited liability company ("BCC"), Bay City Capital Management IV LLC, a Delaware limited liability company ("Management IV"), BayCity Capital Fund IV, L.P., a Delaware limited partnership ("Fund IV"), and Bay City Capital Fund IV Co-Investment Fund, L.P., a Delaware limited partnership ("Co-InvestmentIV") are deemed to be a "group" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management IV is the general partner of Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV. BCC, the manager of Management IV, is also anadvisor to Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV.

F2 · ownership.nature: These securities are held by Fund IV. Dr. Craves disclaims beneficial ownership of these securities held by Fund IV, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in BCC.

SEC source: 0000899243-19-029126 · doc4a.xml · nonDerivative · entry 1

CRAVES FRED B · CIK 0001014095 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 113,472

F1 · acquired: On June 12, 2018, the reporting person filed a Form 4 which inadvertently reported a transaction as an acquisition of common stock by including the "A" notation in Box 4 of Table I. In fact, as reported in this amendment, the transaction should have been reported with a "D" in Box 4 of Table I because the transaction in question was a disposition of common stock.

F2 · ownership.nature: Bay City Capital LLC, a Delaware limited liability company ("BCC"), Bay City Capital Management IV LLC, a Delaware limited liability company ("Management IV"), Bay City Capital Fund IV, L.P., a Delaware limited partnership ("Fund IV"), and Bay City Capital Fund IV Co-Investment Fund, L.P., a Delaware limited partnership ("Co-Investment IV") are deemed to be a "group" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management IV is the general partner of Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV. BCC, the manager of Management IV, is also an advisor to Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV.

F3 · ownership.nature: These securities are held by Co-Investment IV. Dr. Craves disclaims beneficial ownership of these securities held by Co-Investment IV, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in BCC.

SEC source: 0001562180-17-002676 · primarydocument.xml · nonDerivative · entry 2

CRAVES FRED B · CIK 0001014095 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Fred Craves Family Foundation

Disclosed balance after: 30,000

F1 · ownership.nature: Dr. Craves serves as the chief executive officer of the Fred Craves Family Foundation (the "Foundation"). Dr. Craves does not have a pecuniary interest in the shares held by the Foundation and disclaims beneficial ownership over such shares. This report shall not be deemed an admission that the reporting person is the beneficial owner of such shares.

SEC source: 0001562180-17-002676 · primarydocument.xml · nonDerivative · entry 1

CRAVES FRED B · CIK 0001014095 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Fred Craves Family Foundation

Disclosed balance after: 20,000

F1 · ownership.nature: Dr. Craves serves as the chief executive officer of the Fred Craves Family Foundation (the "Foundation"). Dr. Craves does not have a pecuniary interest in the shares held by the Foundation and disclaims beneficial ownership over such shares. This report shall not be deemed an admission that the reporting person is the beneficial owner of such shares.